Palvella Therapeutics, Inc.
PVLA
$23.98
-$0.45-1.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 311.38% | 49.90% | 17.82% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 225.95% | -33.30% | -47.56% | ||
| Operating Income | -225.95% | 33.30% | 47.56% | ||
| Income Before Tax | -139.23% | -154.21% | -781.71% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -139.23% | -154.21% | -781.71% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -139.23% | -154.21% | -781.71% | ||
| EBIT | -225.95% | 33.30% | 47.56% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -130.32% | -343.79% | -620,200.00% | ||
| Normalized Basic EPS | -139.27% | -154.22% | -781.23% | ||
| EPS Diluted | -130.32% | -346.23% | -620,200.00% | ||
| Normalized Diluted EPS | -139.27% | -155.32% | -781.23% | ||
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | ||
| Average Diluted Shares Outstanding | 0.00% | -2.00% | 0.00% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||
